Biosimilars Naming Conventions On FTC Agenda – In More Ways Than One
This article was originally published in RPM Report
Executive Summary
An planned Federal Trade Commission hearing on biosimilar competition will include discussion of the debate over the right approach to non-proprietary names. But FTC may be reopening another naming debate by referring to the hearing topic as “follow-on biologics.”